-+ 0.00%
-+ 0.00%
-+ 0.00%

Angelini Pharma To Acquire Catalyst Pharmaceuticals At $31.50 Per Share In Cash For $4.1B

Benzinga·05/07/2026 07:25:55
Listen to the news
  • The Boards of Directors of Angelini Pharma and Catalyst Pharmaceuticals have unanimously approved the acquisition of Catalyst Pharmaceuticals at 31.50 USD per share in cash, for a total consideration of approximately 4.1 billion USD, representing a premium of 28% to the 30-day volume-weighted average trading price as of April 22, 2026
  • The transaction marks Angelini Pharma's entry into the U.S. market, reinforcing its long-term commitment to Brain Health and its dedication to people living with Rare Diseases
  • Closing is expected in the third quarter of 2026